Alternative ETV6-JAK2 fusions have been identified in both ALL and atypical chronic myelogenous leukemia (CML), that lead to constitutive activation of the JAK2 tyrosine kinase and downstream pathways [76,77]. Here, ETV6 is linked to acute lymphoblastic leukemia.